ABSOLUTE ANTIBODY

Company Overview

Absolute Antibody specializes in antibody reagents, kits and services, adding value to existing antibodies through annotation, validation, sequencing, engineering and recombinant manufacturing. The company unites multiple antibody-centric brands to offer global customers the full breadth of antibody-related products, services and expertise for research, diagnostic and therapeutic applications. It has 21,000 and more recombinant antibody production in run, and nearly 180 different antibody engineering formats being manufactured. As of 2022, Absolute Antibody operates as a subsidiary of Absolute Biotech.

Founded in August 2012 in Cleveland, U.K., Absolute Antibody also offers antibody sequencing, manufacturing, and engineering services to all antibody users, and its ever-growing antibody catalog already includes more than 2,500 antibodies; 30 research-grade biosimilars; and recombinant versions of “classics,” such as anti-phosphotyrosine [PY20], anti-F4/80 [Cl:3A-1], and anti-c-myc [9E10]).

Company's Business Segments

• Antibodies : This segment includes Primary Antibodies, Secondary Antibodies like Anti-Allergen Antibodies, Anti-Coronavirus Antibodies, Anti-Virus Antibodies, Antibodies to Epitope Tags, DNA/RNA Research Antibodies, Immunotherapy Research Antibodies, Murine Bispecific Antibody Reagents, Neuroscience Research Antibodies, Recombinant Antibodies from Human Patients, Recombinant Isotype Controls, Research-Grade Biosimilars, Tumor Marker Antigens
• Antiobody Engineering Services : This segment includes Antibody Humanization Service, Bispecific and Trispecific Antibodies, Codon Optimization Service, Hybridoma Sequencing, Antibody Protein Sequencing, Polyclonal Antibody Sequencing.